Skip to main content


The Fraunhofer Institute for Biomedical Engineering IBMT acts as a device and technology developer and provides solutions answering the needs of industrial and academic partners in the fields of life sciences, biotechnology and biomedical/medical engineering.
Ultrasound research is one is the key activities at IBMT with more than 40 employees in hardware development (electronics, transducers), software development (signal processing, imaging, simulations) and technology transfer (manufacturing technology, regulatory aspects).

Steffen Tretbar

Steffen Tretbar is the head of IBMT´s main Department ultrasound. With a background in ultrasound imaging, signal processing and applications and a strong expertise in regulatory aspects of medical devices, he had been leading R&D projects with industrial partners and national/international consortia for more than 15 years. He will ensure the overall scientific and administrative coordination of IBMT´s activities in AMPHORA.  

Marc Fournelle

Marc Fournelle is heading the Business Area of Biomedical Ultrasound at IBMT. He has a background in ultrasound signal processing, reconstruction techniques and optoacoustic imaging. He will coordinate the development of the ultrasound hardware (multichannel electronics and matrix array probe) in AMPHORA.


Ultrasound is the most widely used medical imaging modality. In addition, recent findings have promoted the usage of ultrasound for therapy (HIFU, thermal ablation of tumors with ultrasound) and therapy monitoring. In AMPHORA, the proof-of-concept of real-time high spatial resolution radiation dosimetry will be made for the first time. The combination of real-time 3D imaging based on matrix arrays and radiation sensitive acoustic contrast agents, whose backscatter signal is modulated by the absorbed dose, will allow the generation of in-vivo real-time quantitative radiation maps for a more precise and safe therapy.

AMPHORA aims to develop a non-invasive in-situ dosimetry system for radiation therapy with the potential of on-line dose assessment by casting ultrasound contrast agents (UCAs) into dose sensing theranostic devices.